GSK241115C40500
- 0.04
- 0.000.00%
GlaxoSmithKline Newsroom
Vaccines Makers Close Lower on Reports RFK Jr May Head HHS
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
GSK Reports Positive Results From Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
Glaxosmithkline (GSK.US) cancer drug Blenrep significantly reduces the risk of death and is expected to regain regulatory approval.
Glaxosmithkline (GSK.US) stated that its blood cancer drug significantly reduced the risk of death in cancer patients when used in combination with another cancer treatment drug.
GlaxoSmithKline To Go Ex-Dividend On November 15th, 2024 With 0.38905 USD Dividend Per Share
November 13th (Eastern Time) - $GlaxoSmithKline(GSK.US)$ is trading ex-dividend on November 15th, 2024.Shareholders of record on November 15th, 2024 will receive 0.38905 USD dividend per share on
GSK Highlights Key Data From Hepatology Portfolio at the AASLD's The Liver Meeting 2024, Emphasising Patient Impact in Areas of High Unmet Need
GSK Gets Health Canada Approval for Blood Cancer Treatment Ojjaara
Top Midday Stories: Tyson Foods Reports Q4 EPS, Revenue Beats; DOJ Reportedly Moving to Block UnitedHealth's Amedisys Acquisition
GSK, Drax, Centrica; What Brokers Said Today
GSK Analyst Ratings
Vesalius Announces Multi-Target Strategic Alliance With GSK to Develop Breakthrough Treatments for People Afflicted With Parkinson's Disease
GSK Target Cut to 1,525p From 2,000p by Jefferies
Jefferies Downgrades GlaxoSmithKline(GSK.US) to Hold Rating, Cuts Target Price to $39.5
GlaxoSmithKline (GSK) Was Downgraded to a Hold Rating at Jefferies
New GSK-sponsored Survey Reveals Unique Gaps in Care and Support Facing Patients With Gynaecologic Cancers
ViiV Healthcare's DOLCE Study Shows 2-Drug Regimen Dovato Is Highly Effective In Treatment-Naïve People With Advanced HIV, Matching 3-Drug Therapy Efficacy At 48 Weeks
Express News | Multiple biomedical collaborations were reached during the Import Expo, involving areas such as hepatitis B and women's health.
FDA recommends stopping the use of common decongestants in cold medicines, glaxosmithkline (GSK.US) and other companies may be affected.
The Food and Drug Administration (FDA) announced on Thursday that it has proposed to remove the oral phenylephrine commonly used in cold and cough syrups from the active ingredients of over-the-counter nasal decongestants and deemed it ineffective.
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)